Overall survival by race in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.

被引：31

作者：

McNamara, Megan Ann

George, Daniel J.

Ramaswamy, Krishnan

Lechpammer, Stanislav

Mardekian, Jack

Schultz, Neil M.

Wang, Li

Baser, Onur

Huang, Ahong

Freedland, Stephen J.

机构：

[1] Duke Univ, Sch Med, Durham, NC USA

[2] Pfizer Inc, New York, NY USA

[3] Pfizer Inc, San Francisco, CA USA

[4] Astellas Pharma Inc, Northbrook, IL USA

[5] STATinMED Res, Plano, TX USA

[6] Univ Michigan, Ann Arbor, MI 48109 USA

[7] Durham VA Med Ctr, Urol Sect, Durham, NC USA

来源：

关键词：

D O I：

10.1200/JCO.2019.37.7_suppl.212

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

212

引用

页数：1